Antibiotice Ia (ATB) - Net Assets
Based on the latest financial reports, Antibiotice Ia (ATB) has net assets worth RON932.07 Million RON (≈ $214.02 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON1.39 Billion ≈ $319.75 Million USD) and total liabilities (RON460.49 Million ≈ $105.73 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Antibiotice Ia (ATB) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON932.07 Million |
| % of Total Assets | 66.93% |
| Annual Growth Rate | 10.06% |
| 5-Year Change | 54.06% |
| 10-Year Change | N/A |
| Growth Volatility | 10.77 |
Antibiotice Ia - Net Assets Trend (2020–2025)
This chart illustrates how Antibiotice Ia's net assets have evolved over time, based on quarterly financial data. Also explore Antibiotice Ia total assets for the complete picture of this company's asset base.
Annual Net Assets for Antibiotice Ia (2020–2025)
The table below shows the annual net assets of Antibiotice Ia from 2020 to 2025. For live valuation and market cap data, see ATB company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | RON932.07 Million ≈ $214.02 Million |
+4.22% |
| 2024-09-30 | RON894.31 Million ≈ $205.35 Million |
+5.59% |
| 2023-09-30 | RON846.96 Million ≈ $194.48 Million |
+32.04% |
| 2022-09-30 | RON641.43 Million ≈ $147.28 Million |
+6.02% |
| 2021-09-30 | RON604.99 Million ≈ $138.92 Million |
+4.80% |
| 2020-09-30 | RON577.27 Million ≈ $132.55 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Antibiotice Ia's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 26998917200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON221.23 Million | 23.73% |
| Other Components | RON710.85 Million | 76.27% |
| Total Equity | RON932.07 Million | 100.00% |
Antibiotice Ia Competitors by Market Cap
The table below lists competitors of Antibiotice Ia ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sanghvi Movers Limited
NSE:SANGHVIMOV
|
$332.24 Million |
|
Esso (Thailand) Public Company Limited
BK:BSRC
|
$332.25 Million |
|
Maui Land & Pineapple Company Inc
NYSE:MLP
|
$332.27 Million |
|
Sun Tekstil Sanayi ve Ticaret A.S.
IS:SUNTK
|
$332.71 Million |
|
Lowland Investment Co
LSE:LWI
|
$332.16 Million |
|
CARYSIL LIMITED
NSE:CARYSIL
|
$331.90 Million |
|
Baader Bank Aktiengesellschaft
F:BWB
|
$331.82 Million |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
$331.75 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Antibiotice Ia's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 894,308,823 to 932,073,712, a change of 37,764,889 (4.2%).
- Net income of 51,769,472 contributed positively to equity growth.
- Dividend payments of 15,948,819 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON51.77 Million | +5.55% |
| Dividends Paid | RON15.95 Million | -1.71% |
| Other Changes | RON1.94 Million | +0.21% |
| Total Change | RON- | 4.22% |
Book Value vs Market Value Analysis
This analysis compares Antibiotice Ia's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.55x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.51x to 1.55x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-09-30 | RON0.86 | RON2.16 | x |
| 2021-09-30 | RON0.90 | RON2.16 | x |
| 2022-09-30 | RON0.96 | RON2.16 | x |
| 2023-09-30 | RON1.26 | RON2.16 | x |
| 2024-09-30 | RON1.33 | RON2.16 | x |
| 2025-09-30 | RON1.39 | RON2.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Antibiotice Ia utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.55%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.02%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.49x
- Recent ROE (5.55%) is below the historical average (7.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 4.57% | 7.75% | 0.39x | 1.49x | RON-31.34 Million |
| 2021 | 4.95% | 8.18% | 0.41x | 1.48x | RON-30.56 Million |
| 2022 | 8.02% | 10.64% | 0.56x | 1.34x | RON-12.67 Million |
| 2023 | 9.57% | 13.50% | 0.53x | 1.35x | RON-3.61 Million |
| 2024 | 11.43% | 15.14% | 0.53x | 1.43x | RON12.77 Million |
| 2025 | 5.55% | 8.02% | 0.46x | 1.49x | RON-41.44 Million |
Industry Comparison
This section compares Antibiotice Ia's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $724,246,398
- Average return on equity (ROE) among peers: 17.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Antibiotice Ia (ATB) | RON932.07 Million | 4.57% | 0.49x | $332.19 Million |
| Biofarm Bucure (BIO) | $257.23 Million | 19.78% | 0.35x | $323.55 Million |
| ZENTIVA S.A. (SCD) | $1.19 Billion | 16.17% | 0.26x | $723.41 Million |
About Antibiotice Ia
Antibiotice S.A. produces and sells medicinal products in Romania and internationally. The company provides generic prescription medicines comprising anti-infectives, including drugs for the treatment of tuberculosis, as well as cardiovascular drugs, digestive tract and metabolism class, preparations for the treatment of gynecological diseases, and dermatological and central nervous system prepar… Read more